Become A Wiser, More Profitable Investor

Serological survey to estimate SARS-CoV-2 infection and antibody seroprevalence at a large public university: A cross-sectional study

Objective This study investigated the seroprevalence of SARS-CoV-2 antibodies among adults over 18 years. Design Prospective cohort study. Settings A large public university. Participants This study took volunteers over 5 days and recruited 1064 adult participants. Primary outcome measures Seroprevalence of SARS-CoV-2-specific antibodies due to previous exposure to SARS-CoV-2 and/or vaccination. Results The seroprevalence of the antireceptor binding domain (RBD) antibody was 90% by a lateral flow assay and 88% by a semiquantitative chemiluminescent immunoassay. The seroprevalence for antinucleocapsid was 20%. In addition, individuals with previous natural COVID-19 infection plus vaccination had higher anti-RBD antibody levels compared with those who had vaccination only or infection only.

BMJ     Aug 04, 2023